Leerink Partners Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $862.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target decreased by stock analysts at Leerink Partners from $980.00 to $862.00 in a research note issued to investors on Tuesday. The brokerage presently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Partners’ price objective points to a potential upside of 23.03% from the company’s previous close.

A number of other brokerages have also issued reports on REGN. Evercore ISI cut their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Bank of America reiterated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Royal Bank of Canada reduced their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $983.65.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded up $33.79 during midday trading on Tuesday, reaching $700.64. The company’s stock had a trading volume of 541,739 shares, compared to its average volume of 873,813. Regeneron Pharmaceuticals has a one year low of $642.00 and a one year high of $1,211.20. The company has a market cap of $76.99 billion, a price-to-earnings ratio of 17.23, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a 50 day moving average price of $720.81 and a 200 day moving average price of $921.72. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Mizuho Securities USA LLC grew its position in shares of Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Simplify Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after buying an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $1,334,000. Finally, Daiwa Securities Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 12.3% during the third quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock worth $21,428,000 after buying an additional 2,234 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.